Atlas Trials

Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer

Clinical trial NCT00842998 · UNKNOWN

Trial details

NCT number
NCT00842998
Sponsor
Azienda Ospedaliera Ordine Mauriziano di Torino
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Breast Cancer
Start date
2009-02-01
Primary completion
2011-12-01
Enrollment
120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.